Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chemotherapy
siRNA against NF-kappaB p65 subunit enhances sensitivity to chemotherapeutics
August 6th, 2004
siRNA directed against the NF-kappaB p65 subunit enhances sensitivity to chemotherapeutics. "In preclinical tumor models, inhibition of nuclear factor-kappaB (NF-kappaB) has been associated with increased sensitivity to chemotherapeutic agents such as irinotecan (CPT-11). "This is based on the fact that a variety of chemotherapy agents such as CPT-11 activate NF-kappaB to result in the expression of genes such as c-IAP1 and c-IAP2 that might be responsible for the inhibition of chemotherapy-induced apoptosis," researchers in the United States report. "In this study," wrote J. Guo and coworkers, "RNA interference [small interfering...
Source: Genomics & Genetics Weekly (2004-08-06)
|
